Protocolli GOIRC-sponsored con arruolamento aperto

GOIRC-08-2018  CABOGEN (osservazionale)

Retrospective analysis of patients with metastatic renal cell carcinoma treated with CABOzantinib: a GENomic signature for describing long-term response

Centro Coordinatore: Reggio Emilia

CABOGEN Valutazione d’impatto privacy

CABOGEN Informativa pazienti non contattabili

GOIRC-02-2019 ORTOBREAST (osservazionale)

Quando l’attenzione per il cibo dopo il tumore al seno può diventare una patologia: proposta di studio osservazionale prospettico multicentrico sulle donne affette da tumore della mammella in fase precoce, nei confronti del loro rapporto con il cibo dopo la malattia

Centro Coordinatore: Modena

GOIRC-03-2019 ATEZOMESO

Phase III study with atezolizumab versus placebo in malignant pleural mesothelioma patients after pleurectomy/decortication

Centro Coordinatore: Reggio Emilia

GOIRC-05-2020 DUPLE

A multicenter phase II, single arm study of Durvalumab with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) – DUPLE trial

Centro Coordinatore: Bologna

GOIRC-01-2021 DURVASCC

Agnostic therapy in a phase II, multicenter, single-arm study in first-line treatment of durvalumab (MEDI 4736) in association with carboplatin or cisplatin and etoposide in patients affected by extensive stage - extrapulmonary small cell carcinoma (EPSCC)

Centro Coordinatore: Reggio Emilia

GOIRC-01-2023  CARRY-ON

Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line platinum-etoposide chemotherapy and a PD-L1 inhibitor – CARRY ON study

Centro Coordinatore: Bologna